Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03899402 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Triple Therapy in T1DM

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Mar 31, 2026 to Jun 30, 2026v7
  2. Primary completion date: Dec 31, 2024 to Jan 31, 2026v6 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 114 to confirmed 78
    • Study completion date: Mar 1, 2025 to Mar 31, 2026
    • Site details revised
  3. Primary completion date: Dec 31, 2023 to Dec 31, 2024
    • Primary endpoint revised
    • Study completion date: Mar 1, 2024 to Mar 1, 2025
    • Secondary endpoints: 32 to 22
    v5
  4. Collaborators: 1 to 2v4
  5. Primary completion date: May 1, 2022 to Dec 31, 2023
    • Study completion date: May 1, 2022 to Mar 1, 2024
    • Site contact updated
    v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
Trial Details
NCT Number NCT03899402
Lead Sponsor State University of New York at Buffalo
Collaborators: University of Glasgow, Juvenile Diabetes Research Foundation
Conditions
(from sponsor)		 Type 1 Diabetes Mellitus
Related terms Diabetes Mellitus, Type 1
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov